Novavax, Inc. (NASDAQ:NVAX) Director Sells $43,200.00 in Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 5,400 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Novavax Trading Up 6.6 %

NASDAQ:NVAX traded up $0.53 during midday trading on Thursday, hitting $8.57. 3,813,721 shares of the company were exchanged, compared to its average volume of 9,060,255. Novavax, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $23.86. The company has a market capitalization of $1.37 billion, a PE ratio of -3.79 and a beta of 2.02. The company has a fifty day simple moving average of $8.74 and a 200 day simple moving average of $11.40.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to analysts’ expectations of $65.80 million. The company’s revenue for the quarter was down 54.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.26) earnings per share. As a group, equities research analysts expect that Novavax, Inc. will post -1.44 EPS for the current year.

Analyst Upgrades and Downgrades

NVAX has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. B. Riley restated a “buy” rating and set a $26.00 price target (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, Jefferies Financial Group decreased their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.83.

Hedge Funds Weigh In On Novavax

Hedge funds and other institutional investors have recently bought and sold shares of the company. Amalgamated Bank increased its position in Novavax by 26.9% during the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,036 shares during the period. Ensign Peak Advisors Inc grew its position in Novavax by 3.0% during the second quarter. Ensign Peak Advisors Inc now owns 44,900 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 1,300 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 1,598 shares during the period. Victory Capital Management Inc. boosted its position in Novavax by 12.0% during the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 2,072 shares in the last quarter. Finally, Banque Cantonale Vaudoise increased its position in shares of Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 2,500 shares in the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.